New market launch: Tiefenbacher Pharmaceuticals successfully launches the generic version of Teriflunomide in more than 20 European countries

Tiefenbacher Pharmaceuticals has successfully prepared a day one launch of the generic version of the Multiple Sclerosis (MS) medication Teriflunomide (reference brand name: Aubagio). This complex generic launch explicitly follows Tiefenbacher Group`s strategy to make high quality pharmaceuticals better affordable and better available for patients worldwide. Moreover, the low cost of generic medications promotes patient affordability and contributes to lower per capita healthcare spending.

Generally speaking, generics are therapeutically equivalent to their branded counterparts with a lower price due to losing patent protection. Furthermore the low cost of generic medications promotes patient affordability. Also it contributes to lower per capita healthcare spending.

Teriflunomide is used to treat Multiple Sclerosis (MS), a chronic disease that effects the central nervous system. The 14 mg film coated tablets are developed and produced in Tiefenbacher Group`s own sites and will be marketed by our partners, well-known international pharmaceutical companies. Our product has already been successfully launched in the US, Canada, Mexico, and Australia – all with strict US Food and Drug Administration (FDA) standards. Further markets will follow shortly to increase the global availability of our high-quality generic medicines even more.

Tiefenbacher Pharmaceuticals is committed to continuously making high-quality medicines better affordable, better global availability, and better than before. We will keep you updated about launches of this and other products in further international markets.

TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets.  

For more information about our finished dosage forms (FDF) including highly potent drugs and healthcare solutions, please contact us at or visit us on

About Tiefenbacher Group – Pioneering Healthcare since 1963

Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices. Our purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.

For further information about TIEFENBACHER GROUP and our solutions for better healtcare and our in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) please contact us by email at or visit us on: